Sanofi Releases Q1 2026 Briefing Document Ahead of April 23 Results
Sanofi announces the release of its 'Q1 2026 Briefing Document' aimed at assisting investors with financial modeling. This quarterly document addresses non-comparable items, the impact of foreign currencies, and the number of shares.
Availability of the Q1 2026 Briefing Document
The 'Q1 2026 Briefing Document' has been made available on the 'Investors' page of Sanofi's website. Prepared each quarter, it is designed to assist in the financial modeling of quarterly results. It addresses non-comparable items, the impact of foreign currencies, and the number of shares. Sanofi's Q1 2026 results will be released on April 23, 2026.
Sanofi's Commitment to Innovation and Long-term Growth
Sanofi is a biopharmaceutical company that innovates in R&D and leverages AI on a large scale to enhance people's lives and achieve long-term growth. The company utilizes its deep understanding of the immune system to develop drugs and vaccines that treat and protect millions of people worldwide, with an innovative pipeline. The team is driven by the goal of advancing the miracles of science to improve people’s lives by addressing the most pressing health, environmental, and societal challenges.
